Spinogenix, Inc.的封面图片
Spinogenix, Inc.

Spinogenix, Inc.

生物技术研究

Los Angeles,California 1,100 位关注者

Developing a new class of therapeutics for neurodegenerative and psychiatric diseases

关于我们

Who we are In most neurodegenerative diseases we lose connections - synapses – between neurons, a process that contributes to declines in cognition and motor function that characterize these diseases. At Spinogenix we are developing first-in-class, novel small molecule drugs (SPGs) that restore synapses to improve and potentially restore cognitive and motor function. Our approach is unique for diseases of the central nervous system. Mission Our mission is to create transformative therapeutics for diseases involving synaptic loss and dysfunction. Our approach is focused on regenerating synapses to reverse declines in cognitive and motor function. This approach is unique among the many therapeutics that are being developed for neurodegenerative conditions, which mostly aim to slow the degenerative process. We envision the use of SPGs as a monotherapy or in combination with other therapeutics that target disease-specific degenerative processes. Our Science In contrast to much research focused on alleviating the symptoms of neurodegenerative disease, we seek to develop therapies that impact the underlying disease and fundamentally change treatment paradigms by restoring neuronal connections regardless of the underlying cause of synapse loss. Spinogenix has discovered compounds (SPGs) that restore lost synapses. We have demonstrated the effectiveness of these “spinogenic” molecules in cells and in multiple animal models of neurodegeneration. SPGs have a novel molecular target and their mechanism of action is well understood and unique. This mechanism would be operative in all diseases where synapse loss occurs, irrespective of the pathological basis of synapse loss.

网站
https://spinogenix.com/
所属行业
生物技术研究
规模
2-10 人
总部
Los Angeles,California
类型
私人持股
创立
2016
领域
Therapeutics、Neurodegeneration、Amyloids、Neurorestorative、ALS、Schizophrenia、Depression、Alzheimer's、Parkinson's和Synapses

地点

  • 主要

    1901 Avenue of the Stars

    US,California,Los Angeles,90067

    获取路线

动态

  • 查看Spinogenix, Inc.的组织主页

    1,100 位关注者

    We are continually inspired by leaders like Dan Doctoroff, whose resilience and vision extend far beyond city skylines. His determination to transform the future of #ALS research through Target ALS aligns with our fight to keep pushing the field forward with new possibilities.

    查看Target ALS的组织主页

    10,252 位关注者

    A Visionary Leader. A Champion for ALS. Dan Doctoroff’s life has been defined by bold ideas and extraordinary impact. As Deputy Mayor of New York City, he reimagined what was possible—driving the redevelopment of the World Trade Center site, Hudson Yards, the High Line, and Brooklyn Bridge Park. His leadership reshaped a city. But his greatest challenge would come not from the city, but from a diagnosis. ALS—a rare disease that took his father and uncle—became his reality. When symptoms first appeared, they disrupted a life built on momentum. But Dan’s response was not anger or despair. It was action. He founded Target ALS, not just to fight his own battle, but to confront a rare disease that devastates too many families. With the same relentless drive that built iconic landmarks, he is breaking down barriers to accelerate ALS research—driving collaboration, innovation, relentlessly in pursuit of effective treatments. Video courtesy of ALS United Greater New York #ALS #ALSResearch #EveryoneLives #NYC

  • 查看Spinogenix, Inc.的组织主页

    1,100 位关注者

    Progress in #ALS treatment doesn’t happen in isolation—it requires collaboration, vision, and bold new approaches. At Spinogenix, we’re pioneering synapse regeneration to restore lost neural connections, offering a promising path forward in ALS treatment.?#SPG302, designed to restore synaptic density with the hope to improve cognitive, motor, and respiratory function, represents a novel therapeutic approach to address the unmet need for theALS community. In a recent conversation Stella Sarraf, PhD and Dan Doctoroff, a pioneering leader in ALS and founder of Target ALS, discuss the urgent need for innovative research and cross-disciplinary collaboration to accelerate breakthroughs. Dr. Doctoroff’s leadership has been instrumental in driving critical funding and partnerships in the fight against this devastating disease. Learn more about our shared mission and how SPG302 is shaping the future of ALS treatment | https://lnkd.in/erA97avD. #ALS #ALSAwareness #ALSResearch #Neurodegeneration # #ALSCommunity #CollaborationForACure #EndALS #Neuroscience #ALSDrugResearch #RegenerativeMedicine

    • 该图片无替代文字
  • Fragile X News Today spotlights the promising impact of #SPG601 in reducing abnormal brain activity in Fragile X syndrome, the leading inherited form of intellectual disability and a known cause of autism. This coverage underscores the growing recognition of our work in advancing a new treatment that works at the synaptic level to improve core symptoms and challenging behaviors with the hope to enhance the overall quality of life for those affected. Read the full article here | https://lnkd.in/eH7qjRyV. #FragileX #Neurology #SynapseRestoration #RegenerativeMedicine #Neurodegeneration #FXS

    • 该图片无替代文字
  • The search for effective treatments for #ALS continues, but progress has been challenging. The recent results from the HEALEY ALS Platform Trial underscore the difficulty of developing new therapies for this devastating condition. And current therapies available to most ALS patients offer only a very modest extension of life. Despite setbacks, innovation continues, and new approaches offer hope. Spinogenix’s SPG302 is a first-in-class synaptic regenerative drug tablet aimed at reversing declines in cognitive, motor, and respiratory function. Unlike therapies that focus on slowing degeneration, SPG302 is the first treatment designed to potentially restore function, offering new hope for people with ALS. SPG302 has received FDA orphan drug designation and is currently in phase 2 clinical trials. Learn more about our ALS mission and the importance of synapse regeneration | https://lnkd.in/gbfiaUb4. #Neuroscience #Biotech #Spinogenix #SynapseRestoration #RegenerativeMedicine #Neurodegeneration

    • 该图片无替代文字
  • Schizophrenia affects millions worldwide, yet existing treatments primarily focus on symptom management rather than addressing the underlying biology. Research shows that synapse loss is a key factor in cognitive deficits and functional decline. At Spinogenix, we are pioneering the first synaptic regenerative therapy for schizophrenia, with the potential to restore cognitive function, reduce symptoms and improve patient outcomes. Learn more about how synapse regeneration could transform schizophrenia treatment | https://lnkd.in/eruCU7sV. #Schizophrenia #Neuroscience #SynapseRegeneration #Spinogenix #RegenerativeMedicine

    • 该图片无替代文字
  • 查看Spinogenix, Inc.的组织主页

    1,100 位关注者

    Current Alzheimer’s treatments focus on slowing progression—but what if we could go beyond that? At Spinogenix, we’ve developed the first synaptic regenerative therapy designed to restore lost cognitive function. SPG302 is a once-daily tablet that aims to rebuild synapses—the brain’s key connections for memory and cognition—offering hope?for a more accessible and effective alternative to?current treatments. Our Phase 2 clinical trials in Australia are advancing this groundbreaking approach. ? Learn more about how targeting synapses could change the future of Alzheimer’s treatment |?https://lnkd.in/g8Uhi4r5. ? #Alzheimers #Neuroscience #ClinicalTrials #SynapseRestoration #Spinogenix #RegenerativeMedicine

    • 该图片无替代文字
  • 查看Spinogenix, Inc.的组织主页

    1,100 位关注者

    Last night at the NIH Fragile X Centers of Excellence Update conference, Dr. Craig Erickson, Spinogenix Chief Medical Advisor, announced promising Phase 2 study results for SPG601, a new therapy for Fragile X syndrome (FXS): a genetic disorder, the leading inherited cause of intellectual disability, and a known cause of autism. SPG601 is designed to improve core symptoms of FXS by targeting a key molecular dysfunction at the synaptic level. With no approved treatments currently available, Spinogenix is committed to advancing this much-needed therapy to enhance the overall quality of life for those affected. Dr. Erickson, who served as principal investigator of the study conducted at Cincinnati Children's, said, “This is the strongest test result to date demonstrating a therapy normalizing gamma band activity, which is directly associated with learning, memory, and typical brain activity.” The FDA granted Orphan Drug and Fast Track designation to SPG601, and Spinogenix and Cincinnati Children’s are completing analysis of the full study results in preparation for publication. Stay tuned for what’s ahead | https://lnkd.in/gWNX8P8V. #FragileX #FXS #Neuroscience #FragileXResearch #CincinnatiChildrens #FragileXCommunity #PharmaInnovation #ClinicalResearch #ClinicalTrials

    • 该图片无替代文字
  • 查看Spinogenix, Inc.的组织主页

    1,100 位关注者

    We are thrilled to share that Dr. Craig Erickson, Spinogenix Chief Medical Advisor, will present our Phase 2 study results of SPG601 to treat #FXS at the NIH Fragile X Centers of Excellence Conference on February 10. With Orphan Drug and Fast Track designations granted from the FDA, SPG601 and this research, conducted at Cincinnati Children's, represent an important step forward in advancing hope for a novel new therapy for the Fragile X community. Dr. Erickson is the principal investigator of the SPG601 Phase 2 study in FXS and also the research director and an associate professor in the Division of Child and Adolescent Psychiatry at Cincinnati Children’s, where he and his lab team study translational treatment development for neurodevelopmental disorders, with a focus on FXS and autism spectrum disorder. Families, researchers, and advocates interested in learning more about this breakthrough study can register for free to attend the webinar. Sign up here |?https://lnkd.in/gvq-KDD8. #FragileX #FragileXResearch #CincinnatiChildrens #FragileXCommunity

    • 该图片无替代文字
  • 查看Spinogenix, Inc.的组织主页

    1,100 位关注者

    Recent FDA approvals mark a major milestone in the fight against #AlzheimersDisease, and at Spinogenix, we’re excited about what’s ahead. While these advancements are encouraging, the next step is?regenerating the?synapses?lost in AD—which means restoring cognitive function. ? Our Founder & CEO, Dr. Stella Sarraf, PhD, spoke with PharmaShots about our groundbreaking approach,?by?targeting synapses?with the potential to reverse cognitive decline and improve patient outcomes. ? Read the full interview to learn more about our innovative approach |?https://lnkd.in/dfrtHeMR. ? #AlzheimersResearch #Neurodegeneration #Biotech #Innovation #Spinogenix?#regenerativemedicine

    • 该图片无替代文字
  • 查看Spinogenix, Inc.的组织主页

    1,100 位关注者

    #FragileXsyndrome (FXS)?is a common inherited form of #autism, affecting thousands of families worldwide. Individuals with FXS face challenges like severe anxiety, sensory sensitivities, and developmental seizures, placing an immense emotional and financial burden on caregivers. In the U.S. alone, direct family healthcare costs for FXS total $4.1 billion annually. Despite this impact, there are no FDA-approved treatments for FXS—leaving this community underserved. ? At Spinogenix, we’re committed to changing that. Our work focuses on restoring synaptic health, and our innovative therapy, SPG601, recently received FDA Fast Track Designation. This milestone represents hope for families impacted by FXS and autism as we strive to address this critical unmet need. ? Learn more about our science and how we’re advancing solutions for Fragile X:?https://lnkd.in/gZM_R568. ? National Fragile X Foundation, FRAXA Research Foundation, Autism Speaks.

    • 该图片无替代文字

相似主页

查看职位

融资

Spinogenix, Inc. 共 6 轮

上一轮

未知

US$2,800,000.00

Crunchbase 上查看更多信息